Planned 25,000-share Rule 144 sale in ACEL (NASDAQ: ACEL) detailed

Rhea-AI Filing Summary

ACEL has a shareholder filing a notice of proposed sale under Rule 144 for up to 25,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney on the NYSE around January 15, 2026, with an aggregate market value listed at $286,000.00. The filing notes that 83,207,946 common shares were outstanding at the time referenced.

The 25,000 shares were originally acquired on July 1, 2013 in a SPAC transaction with the issuer. Over the prior three months, related sellers using 10b5-1 trading plans completed several sales of 12,500 common shares each on December 11 and 15, 2025, with gross proceeds per block ranging from $137,576.25 to $139,937.50. The signer represents they are not aware of undisclosed material adverse information about the issuer.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	286000.00	83207946	01/15/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2013	SPAC Transaction	Issuer			25000	07/01/2013	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for GRANT PLACE FUND LLC 140 Tower Drive Burr Ridge IL 60527	Common	12/15/2025	12500	139930.00
10b5-1 Sales for CRILLY COURT TRUST 140 Tower Drive Burr Ridge IL 60527	Common	12/15/2025	12500	139937.50
10b5-1 Sales for GRANT PLACE FUND LLC 140 Tower Drive Burr Ridge IL 60527	Common	12/11/2025	12500	137576.25
10b5-1 Sales for CRILLY COURT TRUST 140 Tower Drive Burr Ridge IL 60527	Common	12/11/2025	12500	137578.75

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing for ACEL disclose?

It discloses that a shareholder intends to sell up to 25,000 shares of ACEL common stock under Rule 144, through Morgan Stanley Smith Barney on the NYSE, with an indicated aggregate market value of $286,000.00.

How many ACEL shares are planned to be sold and at what market value?

The filing indicates a planned sale of 25,000 common shares of ACEL, with an aggregate market value shown as $286,000.00.

When were the ACEL shares to be sold under this Form 144 originally acquired?

The 25,000 ACEL common shares were acquired on July 1, 2013 in a SPAC transaction with the issuer.

What does the Form 144 say about ACEL shares outstanding?

It states that 83,207,946 common shares of the issuer were outstanding as referenced in the securities information section.

What recent ACEL share sales are reported for the past three months?

The notice lists multiple 10b5-1 sales of 12,500 ACEL common shares each on December 11 and 15, 2025, with gross proceeds per sale ranging from $137,576.25 to $139,937.50.

What representation does the seller make about ACEL in this Form 144?

By signing, the seller represents that they do not know of any material adverse information about ACEL’s current or prospective operations that has not been publicly disclosed.